<span item_type="fundamental" item_id="2093717d439f6f6423ddc8090438fc04" counter_id="ST/US/JSPRW" env="prod"></span><span item_type="announcement" item_id="549080918326647681" env="prod"></span><p>EPS: As of FY2025 Q2, the actual value is USD -1.74.</p><p>EBIT: As of FY2025 Q2, the actual value is USD -27.08 M.</p><p></p><h3>Cash and Cash Equivalents</h3><ul><li>As of June 30, 2025, Jasper Therapeutics reported cash and cash equivalents totaling $39.5 million.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1788028/000121390025075678/ea025299101ex99-1_jasper.htm"></span></li></ul><h3>Operating Expenses</h3><ul><li>Research and development expenses for the three months ended June 30, 2025, were $21.2 million, compared to $11.3 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1788028/000121390025075678/ea025299101ex99-1_jasper.htm"></span></li><li>General and administrative expenses for the three months ended June 30, 2025, were $5.9 million, compared to $4.7 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1788028/000121390025075678/ea025299101ex99-1_jasper.htm"></span></li><li>Total operating expenses for the three months ended June 30, 2025, were $27.1 million, compared to $16.0 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1788028/000121390025075678/ea025299101ex99-1_jasper.htm"></span></li></ul><h3>Net Loss</h3><ul><li>Jasper reported a net loss of $26.7 million for the three months ended June 30, 2025, with a basic and diluted net loss per share of $1.74.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1788028/000121390025075678/ea025299101ex99-1_jasper.htm"></span></li></ul><h3>Outlook / Guidance</h3><ul><li>Jasper Therapeutics plans to report additional data from the BEACON study and the new patient cohorts in late 2025, which will aid in dose selection for the planned Phase 2b CSU study expected to commence mid-2026.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1788028/000121390025075678/ea025299101ex99-1_jasper.htm"></span></li><li>The company is focusing its resources on the development of briquilimab in mast-cell driven diseases and has halted other clinical and preclinical programs.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1788028/000121390025075678/ea025299101ex99-1_jasper.htm"></span></li><li>Jasper anticipates completing the investigation into the atypical lack of UAS7 reduction in certain cohorts in the second half of 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1788028/000121390025075678/ea025299101ex99-1_jasper.htm"></span></li></ul>

Jasper Therapeutics - CW26 | 8-K: FY2025 Q2 EPS: USD -1.74